BioBlast Pharma (Israel)
Bio Blast Provides Update on Clinical Trial of Cabaletta(TM) for Oculopharyngeal Muscular Dystrophy (OPMD) TEL AVIV, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) — Bio Blast Pharma Ltd. (ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today preliminary findings ...
Basic Information
- Category: Business
- Website: http://bioblast-pharma.com
Documented Facts
- Inception (Wikidata): 2012-01-01 (Source 2: Wikidata Q30286768, revision 2474102079)
- Headquarters location (Wikidata; date unspecified): Tel Aviv (Source 2: Wikidata Q30286768, revision 2474102079; Source 3: Wikidata label: Q33935, revision 2544645445)
- Country (Wikidata; date unspecified): Israel (Source 2: Wikidata Q30286768, revision 2474102079; Source 4: Wikidata label: Q801, revision 2557691295)
- Official website (Wikidata; date unspecified): http://bioblast-pharma.com/ (Source 2: Wikidata Q30286768, revision 2474102079)
Evidence and Sources
- BioBlast Pharma (Israel) — Official Website (official)
- Wikidata Q30286768, revision 2474102079 (knowledge-base)
- Wikidata label: Q33935, revision 2544645445 (knowledge-base)
- Wikidata label: Q801, revision 2557691295 (knowledge-base)
Citation Guidance
Explore Business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about BioBlast Pharma (Israel).
- Canonical profile: https://brandsource.ai/brands/bioblast-pharma-israel
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/bioblast-pharma-israel/json-ld
- Citation profile API: https://brandsource.ai/api/brands/bioblast-pharma-israel/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-23
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Bio Blast Provides Update on Clinical Trial of Cabaletta(TM) for Oculopharyngeal Muscular Dystrophy (OPMD) TEL AVIV, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) — Bio Blast Pharma Ltd. (ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today preliminary findings ...
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 3 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.